While monoclonal antibodies have been approved to treat respiratory syncytial virus (RSV) in infants and young children in Germany, the German regulatory body for vaccinations—the German National ...

RSV significantly affects vulnerable older French adults, often causing repeat hospitalizations. Despite modern treatments, severe RSV illness can trigger lengthy hospital admissions, use of intensive ...

Among adults older adults, a respiratory syncytial virus (RSV) infection increases the risk of cardiovascular events over the ...

Christmas, Kwanzaa, and other end-of-year holidays typically mean travel followed by close indoor contact with friends or loved ones — near-perfect conditions for nasty airborne viruses to spread. And ...

Please provide your email address to receive an email when new articles are posted on . A model predicted 17.5 to 22.6 million symptomatic RSV cases per year amongadults in the U.S. without a vaccine.

Although lack of routine testing and limitations to current diagnostic testing likely lead to underreporting of respiratory syncytial virus, RSV still poses a substantial economic burden. Respiratory ...

For the first study, published yesterday in JAMA Network Open, Danish researchers used national registry data to assess rates ...

Please provide your email address to receive an email when new articles are posted on . The proportion of respiratory infections testing positive for RSV among pregnant people ranged from 0.9% to 10.7 ...

Background. Limited data exist on the burden of respiratory syncytial virus (RSV) illness among pregnant women, to determine their potential benefit from RSV vaccination. We evaluated the incidence of ...

Worldwide, respiratory syncytial virus (RSV) causes a significant burden of disease among infants. According to estimates, more than 101,000 children under five die every year. Although more than 97% ...